AnaptysBio, Inc. (ANAB)

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late

Campbell and CO Investment Adviser LLC bought a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,281 shares of the biotechnology company's stock, valued at approximately $560,000. Campbell and CO Investment

AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.

The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as reported.

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Paul Lizzul sold 3,650 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares of the company's stock,

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 14,281 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares of the

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 9,639 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.56, for a total transaction of $439,152.84. Following the completion of the transaction, the insider owned 9,157 shares in the company, valued

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 9,202 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sales of the cancer drug Jemperli.

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 10,000 shares of the company's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $46.00, for a total value of $460,000.00. Following the transaction, the insider directly owned 9,088 shares in the company, valued at $418,048.

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations.